Gary Nachman
Stock Analyst at Raymond James
(3.97)
# 616
Out of 5,042 analysts
95
Total ratings
61.97%
Success rate
8.44%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $31.97 | +56.40% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $227.99 | +9.65% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $291.76 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $3.80 | +426.32% | 2 | Aug 13, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Strong Buy | $60 → $64 | $70.86 | -9.68% | 3 | Jul 31, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $22.52 | +24.33% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $463.43 | -35.70% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $5.00 | +300.00% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $21.74 | +70.19% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $15.52 | +22.42% | 1 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $29.68 | +1.08% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $6.84 | +2.34% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $138.53 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $10.55 | -62.09% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $13.53 | +121.73% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $5.66 | +465.37% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $10.35 | +35.27% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $18.95 | -47.23% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $29.97 | +0.10% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.44 | +21,702.33% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $6.20 | +29.03% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $24.52 | -14.36% | 5 | May 11, 2020 |
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $31.97
Upside: +56.40%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $227.99
Upside: +9.65%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $291.76
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $3.80
Upside: +426.32%
Ionis Pharmaceuticals
Jul 31, 2025
Maintains: Strong Buy
Price Target: $60 → $64
Current: $70.86
Upside: -9.68%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $22.52
Upside: +24.33%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $463.43
Upside: -35.70%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $5.00
Upside: +300.00%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $21.74
Upside: +70.19%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $15.52
Upside: +22.42%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $29.68
Upside: +1.08%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $6.84
Upside: +2.34%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $138.53
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $10.55
Upside: -62.09%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $13.53
Upside: +121.73%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $5.66
Upside: +465.37%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $10.35
Upside: +35.27%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $18.95
Upside: -47.23%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $29.97
Upside: +0.10%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.44
Upside: +21,702.33%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $6.20
Upside: +29.03%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $24.52
Upside: -14.36%